Mumps virus ingredient vaccine for human, and its preparation method and uses

A mumps virus and vaccine technology, which is applied in the direction of antiviral agents, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve the differences of different immunological effects, the immunological effect is not the best, and the incidence rate is reduced and other problems, to achieve the effect of good quality, high effectiveness, and reduced side effects

Active Publication Date: 2006-10-11
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, with the widespread application of this attenuated live vaccine in the population and the corresponding reduction in incidence, it may, like other similar virus live vaccines, have virulence changes and form a specific s...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mumps virus ingredient vaccine for human, and its preparation method and uses
  • Mumps virus ingredient vaccine for human, and its preparation method and uses
  • Mumps virus ingredient vaccine for human, and its preparation method and uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] ——Virus inactivation, lysis and purification

[0035] After the harvested virus liquid has been tested for titer and sterility, add formalin stock solution at 1:2000 (V / V), inactivate at 37°C for 7 days, take samples every 2 hours on the first day, and start on the second day Samples were taken daily to determine the virus inactivation curve, e.g. figure 1shown. After 7 days, the inactivated virus was concentrated by filtration and concentrated 100 times on the basis of the original volume, and the inactivated virus solution was added according to the proportion of TritonX-100 2%, SDS 1%, and allowed to react at room temperature for 2 hours. After the treatment, the inactivated virus liquid was filtered by the Sapharose4B column, and the separation results of the virus lysate were shown in Table 1, and the analysis results of the hemagglutination test were shown in Table 2. It was determined that the separated samples were taken, analyzed by PAGE-SDS (12%) electropho...

Embodiment 2

[0039] ——Preparation of Experimental Mumps Virus Vaccine

[0040] According to the protein concentration of the semi-finished vaccine, dilute to 100μl / ml with physiological saline, and prepare 10.87mg / ml of Al(OH) at the same time 3 , the two are mixed in double (V / V) to make an experimental component vaccine, which is the developed mumps virus component vaccine of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to view more

Abstract

The invention relates to a mumps virus ingredient vaccine for human, and its preparation method and uses, wherein the preparing process comprises isolating a parotiditis virus from human body infected by parotiditis virus through conventional methods, adapting the virus to Vero cell culture to prepare single-layer static or rotary Vero cell culture, carrying out virus deactivation, decomposition and purification, predicating the two antigenic components of HN and NP by means of molecular weights, using the antigen composition as the semi-finished vaccine after protein content measurement according to the semi-finished vaccine protein concentration, diluting to 100mul/ml with physiological saline, formulating Al(OH)3 with a concentration of 10.87mg/ml simultaneously, finally mixing the two formulations.

Description

technical field [0001] The invention relates to the field of biotechnology, more specifically, the invention relates to a human mumps virus component vaccine. Meanwhile, the present invention also relates to the preparation method and application of the vaccine. Background technique [0002] The mumps vaccine is one of the viral vaccines routinely given to children worldwide. At present, the use of this vaccine is in the form of attenuated live vaccine in all countries. Due to its application, the incidence of mumps in children has been successfully controlled in most countries, especially in many areas of developed countries. However, with the widespread application of this attenuated live vaccine in the population and the corresponding reduction in incidence, it may, like other similar virus live vaccines, have virulence changes and form a specific subtype in the population. possibility. In addition, different strains of this type of vaccine als...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/155A61P31/14
Inventor 李琦涵马绍辉刘龙丁梁燕王丽春董承红姜莉施海晶赵红玲王晶晶廖芸纳锐雄
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap